---
document_datetime: 2024-02-19 16:19:52
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/briumvi-epar-all-authorised-presentations_en.pdf
document_name: briumvi-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.778759
conversion_datetime: 2025-12-27 14:49:35.194993
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|---------------------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/23/1730/001 | Briumvi           | 150 mg     | Concentrate for solution for infusion | Intravenous use           | Vial (glass)          | 6 ml (25 mg/ml)           | 1 vial      |
| EU/1/23/1730/002 | Briumvi           | 150 mg     | Concentrate for solution for infusion | Intravenous use           | Vial (glass)          | 6 ml (25 mg/ml)           | 3 vials     |